MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.05
-0.14 (-1.25%)
At close: Feb 11, 2026, 4:00 PM EST
11.34
+0.29 (2.65%)
After-hours: Feb 11, 2026, 6:32 PM EST

MiNK Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
5.784.317.437.834.641.29
Research & Development
5.656.3415.4923.1213.979.51
Other Operating Expenses
1.010.64----
Operating Expenses
12.4411.2922.9230.9518.6110.8
Operating Income
-12.44-11.29-22.92-30.95-18.61-10.8
Interest Expense
-----2.43-2.44
Interest & Investment Income
0.110.170.460.25--
Currency Exchange Gain (Loss)
-----0.410.49
Other Non Operating Income (Expenses)
-0.020.15-0-0.090.630.35
EBT Excluding Unusual Items
-12.36-10.97-22.46-30.78-20.82-12.4
Gain (Loss) on Sale of Assets
-0.19----
Other Unusual Items
---2.79-9.4-3.84
Pretax Income
-12.36-10.78-22.46-27.99-30.21-16.24
Net Income
-12.36-10.78-22.46-27.99-30.21-16.24
Net Income to Common
-12.36-10.78-22.46-27.99-30.21-16.24
Shares Outstanding (Basic)
443332
Shares Outstanding (Diluted)
443332
Shares Change (YoY)
12.09%9.82%2.04%29.38%7.95%0.21%
EPS (Basic)
-3.02-2.86-6.54-8.31-11.61-6.74
EPS (Diluted)
-3.02-2.86-6.54-8.31-11.61-6.74
Free Cash Flow
-5.58-9.56-15.84-19.12-13.08-8.43
Free Cash Flow Per Share
-1.36-2.53-4.61-5.68-5.02-3.50
EBITDA
-12.24-11.07-22.72-30.83-18.53-10.74
D&A For EBITDA
0.20.220.20.120.080.06
EBIT
-12.44-11.29-22.92-30.95-18.61-10.8
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q